Abstract
This review summarizes the emerging roles of NHERF1/EBP50 adaptor protein in tumorigenesis. NHERF1/EBP50 (Na+/H+ exchanger regulating factor 1; ezrin-radixin-moesin (ERM) binding phosphoprotein of 50 kDa) is a PDZ domain-containing protein with physiological localization at the plasma membrane. We discuss in this review the functions of NHERF1/EBP50 as a linker between membrane proteins and the cytoskeleton network, as well as its involvement in different types of cancer, such as breast and liver cancers. Recent evidence obtained from our laboratory and from other groups shows that NHERF1/EBP50 is an important player in cancer progression. It appears that, depending on its subcellular distribution, NHERF1/EBP50 may behave either as a tumor suppressor, when it is localized at the plasma membrane, or as an oncogenic protein, when it is shifted to the cytoplasm. We provide here an overview of the mechanisms by which this adaptor protein controls cell transformation, and propose a model suggesting a dual role of NHERF1/EBP50 in cancer.
Keywords: NHERF1/EBP50, tumorigenesis, membrane proteins, cytoskeleton, liver cancers, cancer progression, oncogenic protein
Current Molecular Medicine
Title: Roles of NHERF1/EBP50 in Cancer
Volume: 8 Issue: 6
Author(s): Maria-Magdalena Georgescu, Fabiana C. Morales, Jennifer R. Molina and Yuho Hayashi
Affiliation:
Keywords: NHERF1/EBP50, tumorigenesis, membrane proteins, cytoskeleton, liver cancers, cancer progression, oncogenic protein
Abstract: This review summarizes the emerging roles of NHERF1/EBP50 adaptor protein in tumorigenesis. NHERF1/EBP50 (Na+/H+ exchanger regulating factor 1; ezrin-radixin-moesin (ERM) binding phosphoprotein of 50 kDa) is a PDZ domain-containing protein with physiological localization at the plasma membrane. We discuss in this review the functions of NHERF1/EBP50 as a linker between membrane proteins and the cytoskeleton network, as well as its involvement in different types of cancer, such as breast and liver cancers. Recent evidence obtained from our laboratory and from other groups shows that NHERF1/EBP50 is an important player in cancer progression. It appears that, depending on its subcellular distribution, NHERF1/EBP50 may behave either as a tumor suppressor, when it is localized at the plasma membrane, or as an oncogenic protein, when it is shifted to the cytoplasm. We provide here an overview of the mechanisms by which this adaptor protein controls cell transformation, and propose a model suggesting a dual role of NHERF1/EBP50 in cancer.
Export Options
About this article
Cite this article as:
Georgescu Maria-Magdalena, Morales C. Fabiana, Molina R. Jennifer and Hayashi Yuho, Roles of NHERF1/EBP50 in Cancer, Current Molecular Medicine 2008; 8 (6) . https://dx.doi.org/10.2174/156652408785748031
DOI https://dx.doi.org/10.2174/156652408785748031 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Withdrawal Notice: Reconnoitering the Role of Endothelin in Obesity
Current Pharmaceutical Design MicroRNAs in Lymphoma: Regulatory Role and Biomarker Potential
Current Genomics Restoring TRAIL Induced Apoptosis Using Naturopathy. Hercules Joins Hand with Nature to Triumph Over Lernaean Hydra
Current Genomics The Role of JNK Signalling in Responses to Oxidative DNA Damage
Current Drug Targets Metal Based Frameworks for Drug Delivery Systems
Current Topics in Medicinal Chemistry Phytometabolites Targeting the Warburg Effect in Cancer Cells: A Mechanistic Review
Current Drug Targets Recent Developments of Rebeccamycin Analogues as Topoisomerase I Inhibitors and Antitumor Agents.
Current Medicinal Chemistry The Role of Notch Signaling Pathway in Epithelial-Mesenchymal Transition (EMT) During Development and Tumor Aggressiveness
Current Drug Targets Cyclophilin function in Cancer; lessons from virus replication
Current Molecular Pharmacology Oncogenic LncRNA CASC9 in Cancer Progression
Current Pharmaceutical Design Epigenetic Targets and their Inhibitors in Cancer Therapy
Current Topics in Medicinal Chemistry Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms
Current Pharmaceutical Design The Clinical Significance of Indocyanine Green Excretion Test in Evaluation of Liver Functional Reserve
Current Signal Transduction Therapy Efficacy of Chemoembolization of Hepatocellular Carcinoma with Drug Eluting Beads
Recent Patents and Topics on Imaging (Discontinued) Flt3 Receptor Tyrosine Kinase as a Drug Target in Leukemia
Current Pharmaceutical Design A Novel H.264-Supported Approach for Detecting and Classifying Hepatic Lesions in Computed Tomographic Images
Current Medical Imaging Potential and Cytotoxicity of cis-Platinum Complex with Anti-tumor Activity in Combination Therapy
Recent Patents on Anti-Cancer Drug Discovery Synthesis, DNA Binding Ability and Anticancer Activity of 2-heteroaryl Substituted Benzimidazoles Linked Pyrrolo[2,1-c][1,4]benzodiazepine Conjugates
Medicinal Chemistry Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology Hematopoietic Stem Cells: Source Matters
Current Stem Cell Research & Therapy